Sign Up for ORTHOPRENEUR news & articles

Choose one or more mailing lists:
ORTHOPRENEUR Advertising Opportunities
ORTHOPRENEUR Product Updates
First Name:
Last Name:
Email Address:
Business Name:
Industry        Surgeon

Your privacy and data is important to us and we will never sell or use your information for any purpose other than stated.

Growth in Orthobiologics Segment Dependent upon Clinical Data, Cost-effectiveness

Posted in Research to Reality | Sep 2015 | Comments (0)

Tags: platelet rich plasmaorthopaedic technologyorthopaedic industry trendsinnovationorthobiologicsminimally invasive

Orthobiologic products reach across all segments in the orthopaedic industry, comprising about ten percent
of the orthopaedic market’s total revenue. The segment is expected to grow in the low–single-digits over the next five years, according to ORTHOWORLD estimates.

To gauge the state of the market and new product trends, we’ve enlisted a panel of three orthobiologic company representatives.

Participants included:

Scott Reynolds, Vice President Marketing, Biologic Therapies
Charles Sherwood, Ph.D., President and Chief Executive Officer, Anika Therapeutics
Jessica Terrazas, New Business Development, Celling Biosciences

ORTHOPRENEUR: What trends do you see in the orthobiologics market?

Scott Reynolds_crop_copy
In August 2014, Biologic Therapies conducted a comprehensive statistical market research survey that was sent to 15,616 orthopaedic surgeons in 70 U.S. markets. The survey revealed two important trends. First, a large majority of participants specialize in sports medicine, which is a good segment of the orthopaedic market for regenerative medicine. Second, eight out of ten participants do not currently use regenerative medicine. However, of the participants not currently using it, nearly half said that they plan to use regenerative medicine within the next 24 months.


Charles Sherwood_crop_copy_copySherwood: We see several clinical, economic and regulatory dynamics shaping the near-term orthobiologics market, including:

  • Demand for more clinically-proven, cost-effective and less complex treatments driven by health care providers, third-party payors and group purchase organizations.
  • Better-informed patients demanding greater influence in their own care, who are much more cognizant of (and have greater access to) topics such as treatment alternatives, product safety, adverse events, new therapies and physician ratings.
  • Shifting preference toward early intervention for treatment of chronic degenerative musculoskeletal diseases.
  • High costs and hurdles in the U.S. regulatory process driving companies to execute clinical trials abroad, which results in a shorter time-to-market for products in overseas jurisdictions and in an increasing number of companies deciding to initially launch products outside the U.S.. 

While orthopaedic medicine has generally become less invasive over the years, orthobiologics have the potential to take the field even further by moving the emphasis from “minimally invasive” therapy to early intervention treatment. Anecdotally, second generation bone graft technology today is resulting in simpler procedures that are increasingly less invasive, while retrospective data analysis suggests that viscosupplements, such as our own ORTHOVISC and MONOVISC, may delay total knee replacement.
A truly successful orthobiologic can challenge orthopaedic medicine’s current implant-based paradigm.

Terrazas: What used to be a field that was undefined is now becoming more established. With those changes, surgeons who started out with platelet rich plasma (PRP), steroids and traditional graft materials with “good handling properties” are now focusing on stem and progenitor cells, proteins and substrates that accentuate their potential. Physicians are more educated on cellular therapy and see the value of not just placing growth factors from PRP in therapeutic applications, but also the value of the stem cell, the real work horse behind regenerative capabilities of the body.

Add comment

Security code